Skip to main content

Advertisement

Table 1 Molecular characteristics of Ig H and IgL rearrangements in CLL mAbs used in these studies

From: Chronic Lymphocytic Leukemia Cells Recognize Conserved Epitopes Associated with Apoptosis and Oxidation

CLL No.a Subse†b IGHV Mut.c status %d Mut. IGHD IGHJ HCDR3 amino acid sequencee IGHf GenBank IGLV IGLJ %d Mut. LCDR3 amino acid sequencee IGLf GenBank
068 6 1–69 U-CLL 0.0 3–16 3 ARGGDYDYVWGSYRSNDAFDI AY553640 K3-20 KJ4 0.0 QQYGSSP_T AY574935
258 6 1–69 U-CLL 0.0 3–16 3 ARGGIYDYVWGSYRPNDAFDI AY055485 K3-20 KJ1 0.0 QQYGSSPGT AY574938
014 9 1–69 U-CLL 0.0 3–03 6 ATKNDFWSGYYEGYYYYYYMDV AF021951 L3-01 LJ1 0.0 QAWDSSTCYV AY043106
246 9 1–69 U-CLL 0.3 3–03 6 ARSDQNY_DFWSGYFRYYGMDV FJ039781 K3-20 KJ1 0.0 QQYGSSPET FJ039795
355 9 1–69 U-CLL 0.0 3–03 6 ARADLPYYDFWSGMY_YYGMDV FJ039784 Kl-05 KJ1 0.0 QQYNSY_QT AJ697904
358 NA 1–69 M-CLL 6.8 1–26 5 AVLPSPLVGATQIWGDY FJ039785 K3-20 KJ1 4.5 QQYGSSPPT AJ697906
154 1 1–18 M-CLL 2.4 6–19 4 AREQWLVLSHFDY AF022009 K1D-39 KJ1 0.0 QQSYSTPPWT AY043164
340 1 1–02 U-CLL 0.3 6–19 4 AREQWLVLKNFDY AY553645 K1D-39 KJ2 0.3 QQSYSTPPYT AY574943
360 1 1–03 U-CLL 0.3 6–19 4 AREQWLVLNYFDY AY553647 K1D-39 KJ2 0.0 QQSYSPPPYT AY574945
270 1 1–02 U-CLL 0.0 5–12 4 ARVQWLGLRHFDY AY055487 K1D-39 KJ2 0.0 QQSYSTPPYT AY574940
D013 28 1–02 U-CLL 0.0 1–26 6 ARQFSGSPTRYYYYYGMDV FJ039793 K4-01 KJ4 0.0 QQYYSTPQT FJ039803
376 NA 1–24 U-CLL 0.0 4–17 1 ATSAFTVTHAEYFQH FJ039787 K3-11 KJ1 0.3 QQRSNWPWT FJ039798
415 NA 1–03 U-CLL 0.0 3–10 4 ARRPESGYSFVTPFDY FJ039788 K1D-39 KJ2 0.0 QQSYSTPPHT FJ039799
366 9 3–21 U-CLL 0.0 3–03 6 ARGVLNY_DFWSVYY_YYGMDV FJ039786 K4-01 KJ4 0.0 QQYYSTPLT FJ039797
282 2 3–21 M-CLL 2.4 1–26 6 ARDANGMDV AY553643 L3-21 LJ3 1.0 QVWDSSSDHPWV AY574941
412 2 3–21 M-CLL 2.0 ND 6 ARDQNGMDV AY553648 L3-21 LJ3 0.7 QVWDSSSDHPWV AY574946
562 NA 3–21 U-CLL 1.7 6–19 5 VRDEITVAATRPCP FJ039789 L3-21 LJ3 1.4 QVWDSSDDHPWV FJ039805
169 NA 3–33 M-CLL 8.8 3–10 4 ARE JJVTGQGGF DY AY055480 K4-01 KJ4 0.0 QQYYSTPLT FJ039794
141 NA 4–34 U-CLL 0.0 2–02 5 ARGDWRIVVVPAAVDTAMAANWFDP AF022005 Kl-27 KJ2 0.3 QKYNSAPRMYT AY043160
D08 NA 4–34 U-CLL 0.0 6–13 4 ARGGRAAAGKGLLDY FJ039792 K3-20 KJ1 0.0 QQYGSSPPRT FJ039802
183 4 4–34 M-CLL 3.1 5–18 6 ARGYGDTPTIRRYYYYGMDV AF021948 K2-30 KJ2 1.7 MQGTHWPPYT AY043097
240 4 4–34 M-CLL 3.1 5–18 6 ARGYADTPVFRRYYYYGMDV AY553641 K2-30 KJ2 2.3 MQGTHWPPYT AY574937
342 4 4–34 M-CLL 2.7 5–18 6 ARGWGDTPMLKRYYYYGLDV AY553646 K2-30 KJ2 2.3 MQGTHWPPYT AY574944
114 8 4–39 U-CLL 0.7 6–13 5 ARRFGYSSSWY_GLDWFDP AY268372 K1D-39 KJ1 0.7 QQSYSTPRT AY043094
657 8 4–39 U-CLL 0.3 6–13 5 ASKTGYSSSWY_GRDWFDP FJ039790 K1D-39 KJ1 0.0 QQSYSTPRT FJ039800
845 8 4–39 U-CLL 0.0 6–13 5 ASSTGYSSSWYSPTNWFDP FJ039791 K1D-39 KJ4 0.0 QQSYSTPRT FJ039801
260 NA 4–b U-CLL 0.0 2–02 6 ARAEIVWPAAYYYYYGMDV FJ039783 Kl-27 JK3 0.0 QKYNSAPQVT FJ039796
255 NA 4–59 M-CLL 4.2 3–22 4 ARHRGYESSGYYSSYFDY FJ039782 L3-01 LJ1 2.2 QAWDSSTW FJ039804
  1. aCLL number (No.).
  2. bNA: Not attributable to a currently defined stereotypic subset (25,26).
  3. cMutation (Mut.) status of IGHV: unmutated (U-CLL) or mutated (M-CLL).
  4. dPercent mutation of IGHV or IGLV as compared with germline according to IMGT (54).
  5. eHCDR3 or LCDR3 amino acid sequences according to IMGT with bold characters indicating non-identical residues among members of the same subset (excluding CLL 014).
  6. fGenBank accession numbers for IGH and IGL nucleotide sequences.